GlassScriptPhysician profile
Stephanie E Chandler
NPI 1023406162
$1,266.70
in general payments reported to CMS, 2019-2025
22 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Family Health provider received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $219 · 2023: $232 · 2024: $288 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $283.92 | 2022-2025 | |
| Novo Nordisk INC | $253.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $78.51 | 2021-2023 | |
| Lilly USA, LLC | $77.18 | 2021-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $74.71 | 2022 | |
| Shield Therapeutics INC | $72.98 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $60.95 | 2025 | Libtayo |
| Biohaven Pharmaceuticals, INC. | $59.16 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $45.52 | 2022-2025 | Airsupra, Breztri |
| Eisai INC. | $45.50 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.14 | 2024 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $22.96 | 2024 | |
| Optinose US, INC. | $19.90 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $17.85 | 2024 | Iovera, Zilretta, Exparel |
| Glaxosmithkline, LLC. | $17.57 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.65 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.14 | 2025 | Spravato |
| Pfizer INC. | $15.61 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.37 | 2021 | |
| Exact Sciences Corporation | $15.31 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $12.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.